Understanding the roles of gingival beta-defensins

References

• Dale BA, Kimball JR, Krisanaprakornkit S, Roberts F, Robinovitch M, O'Neal R, et al.. Localized antimicrobial peptide expression in human gingiva. J Periodontal Res. 2001; 36: 285–94.
   PubMed Web of Science ®Google Scholar
• Diamond G, Zasloff M, Eck H, Brasseur M, Maloy WL, Bevins CL. Tracheal antimicrobial peptide, a cysteine-rich peptide from mammalian tracheal mucosa: peptide isolation and cloning of a cDNA. Proc Natl Acad Sci USA. 1991; 88: 3952–6.
   PubMed Web of Science ®Google Scholar
• Bensch KW, Raida M, Mägert HJ, Schulz-Knappe P, Forssmann WG. hBD-1: a novel beta-defensin from human plasma. FEBS Lett. 1995; 368: 331–5.
   PubMed Web of Science ®Google Scholar
• Ouhara K, Komatsuzawa H, Shiba H, Uchida Y, Kawai T, Sayama K, et al.. Actinobacillus actinomycetemcomitans outer membrane protein 100 triggers innate immunity and production of beta-defensin and the 18-kilodalton cationic antimicrobial protein through the fibronectin-integrin pathway in human gingival epithelial cells. Infect Immun. 2006; 74: 5211–20.
   Web of Science ®Google Scholar
• Devine DA. Antimicrobial peptides in defence of the oral and respiratory tracts. Mol Immunol. 2003; 40: 431–43.
   PubMed Web of Science ®Google Scholar
• Marshall RI. Gingival defensins: linking the innate and adaptive immune responses to dental plaque. Periodontol. 2000 2004; 35: 14–20.
   Google Scholar
• Lehrer RI. Immunology: Peptide gets in shape for self-defence. Nature. 2011; 469: 309–10.
   Web of Science ®Google Scholar
• Vardar-Sengul S, Demirci T, Sen BH, Erkizan V, Kurulgan E, Baylas H. Human beta defensin-1 and -2 expression in the gingiva of patients with specific periodontal diseases. J Periodontal Res. 2007; 42: 429–37.
   Web of Science ®Google Scholar
• Gomes Pde S, Fernandes MH. Defensins in the oral cavity: distribution and biological role. J Oral Pathol Med. 2010; 39: 1–9.
   Web of Science ®Google Scholar
• Pazgier M, Hoover DM, Yang D, Lu W, Lubkowski J. Human β-defensins. Cell Mol Life Sci. 2006; 63: 1294–313.
   PubMed Web of Science ®Google Scholar
• Pazgier M, Li X, Lu W, Lubkowski J. Human defensins: Synthesis and structural properties. Curr Pharm Des. 2007; 13: 3096–118.
   PubMed Web of Science ®Google Scholar
• Yang D, Liu ZH, Tewary P, Chen Q, Rosa G, Oppenheim JJ. Defensin participation in innate and adaptive immunity. Curr Pharmaceutic Des. 2007; 13: 3131–9.
   PubMed Web of Science ®Google Scholar
• Wimley WC, Selsted ME, White SH. Interactions between human defensins and lipid bilayers: evidence for formation of multimeric pores. Protein Sci. 1994; 3: 1362–73.
   PubMed Web of Science ®Google Scholar
• Hancock RE &, Chapple DS. Peptide antibiotics. Antimicrob Agents Chemother. 1999; 43: 1317–23.
   PubMed Web of Science ®Google Scholar
• Schmidt NW, Mishra A, Lai GH, Davis M, Sanders LK, Tran D, et al.. Criterion for amino acid composition of defensins and antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc. 2011; 133: 6720–7.
   Web of Science ®Google Scholar
• Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and cathelicidins. Curr Top Microbiol Immunol. 2006; 306: 27–66.
   PubMed Web of Science ®Google Scholar
• Ouhara K, Komatsuzawa H, Yamada S, Shiba H, Fujiwara T, Ohara M, et al.. Susceptibilities of periodontopathogenic and cariogenic bacteria to antibacterial peptides, β-defensins and LL-37, produced by human epithelial cells. J Antimicrob Chemother. 2005; 55: 888–96.
   PubMed Web of Science ®Google Scholar
• Huang GT, Zhang HB, Kim D, Liu L, Ganz T. A model for antimicrobial gene therapy: demonstration of human beta-defensin 2 antimicrobial activities in vivo. Hum Gene Ther. 2002; 13: 2017–25.
   PubMed Web of Science ®Google Scholar
• Motzkus D, Schulz-Maronde S, Heitland A, Schulz A, Forssmann WG, Jübner M, et al.. The novel β-defensin DEFB123 prevents lipopolysaccharide-mediated effects in vitro and in vivo. FASEB J. 2006; 20: 1701–2.
   PubMed Web of Science ®Google Scholar
• Lee SH, Jun HK, Lee HR, Chung CP, Choi BK. Antibacterial and lipopolysaccharide (LPS)-neutralizing activity of human cationic antimicrobial peptides against periodontopathogens. Int J Antimicrob Agents. 2010; 35: 138–45.
   PubMed Web of Science ®Google Scholar
• Rosenfeld Y, Papo N, Shai Y. Endotoxin (lipopolysaccharide) neutralization by innate immunity host-defense peptides. Peptide properties and plausible models of action. J Biol Chem. 2006; 281: 1636–43.
   PubMed Web of Science ®Google Scholar
• Campos MA, Vargas MA, Regueiro V, Llompart CM, Alberti S, Bengoechea JA. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun. 2004; 72: 7107–14.
   PubMed Web of Science ®Google Scholar
• Lu Q, Darveau RP, Samaranayake LP, Wang CY, Jin L. Differential modulation of human β-defensins expression in human gingival epithelia by Porphyromonas gingivalis lipopolysaccharide with tetra- and penta-acylated lipid A structures. Innate Immun. 2009; 15: 325–35.
   Web of Science ®Google Scholar
• Otto M. Bacterial evasion of antimicrobial peptides by biofilm formation. Curr Top Microbiol Immunol. 2006; 306: 251–8.
   PubMed Web of Science ®Google Scholar
• Maisetta G, Brancatisano FL, Esin S, Campa M, Batoni G. Gingipains produced by Porphyromonas gingivalis ATCC 49417 degrade human-β-defensin 3 and affect peptide's antibacterial activity in vitro. Peptides. 2011; 32: 1073–7.
   Web of Science ®Google Scholar
• Shin JE&, Choi Y. Treponema denticola suppresses expression of human beta-defensin-2 in gingival epithelial cells through inhibition of TNF-α production and TLR2 activation. Mol Cells. 2010; 29: 407–12.
   Web of Science ®Google Scholar
• Shin JE, Kim YS, Oh JE, Min BM, Choi Y. Treponema denticola suppresses expression of human β-defensin-3 in gingival epithelial cells through inhibition of the toll-like receptor 2 axis. Infect Immun. 2010; 78: 672–9.
   PubMed Web of Science ®Google Scholar
• Joly S, Maze C, McCray PB Jr, Guthmiller JM. Human beta-defensins 2 and 3 demonstrate strain-selective activity against oral microorganisms. J Clin Microbiol. 2004; 42: 1024–9.
   PubMed Web of Science ®Google Scholar
• Peyret-Lacombe A, Brunel G, Watts M, Charveron M, Duplan H. TLR2 sensing of F. nucleatum and S. sanguis distinctly triggered gingival innate response. Cytokine. 2009; 46: 201–10.
   Web of Science ®Google Scholar
• Ji S, Shin E, Kim YS, Oh JE, Min BM, Choi Y. Toll-like receptor 2 and NALP2 mediate induction of human beta-defensins by Fusobacterium nucleatum in gingival epithelial cells. Infect Immun. 2009; 77: 1044–52.
   Web of Science ®Google Scholar
• Krisanaprakornkit S, Kimball JR, Weinberg A, Darveau RP, Bainbridge BW, Dale BA. Inducible expression of human β-defensin 2 by Fusobacterium nucleatum in oral epithelial cells: Multiple signaling pathways and role of commensal bacteria in innate immunity and the epithelial barrier. Infect Immun. 2000; 68: 2907–15.
   PubMed Web of Science ®Google Scholar
• Gupta S, Ghosh SK, Scott ME, Bainbridge B, Jiang B, Lamont RJ, et al.. Fusobacterium nucleatum-associated beta-defensin inducer (FAD-I): identification, isolation, and functional evaluation. J Biol Chem. 2010; 285: 36523–31.
   Web of Science ®Google Scholar
• Vankeerberghen A, Nuytten H, Dierickx K, Quirynen M, Cassiman JJ, Cuppens H. Differential induction of human beta-defensin expression by periodontal commensals and pathogens in periodontal pocket epithelial cells. J Periodontol. 2005; 76: 1293–303.
   PubMed Web of Science ®Google Scholar
• Lamont RJ, Chan A, Belton CM, Izutsu KT, Vasel D, Weinberg A. Porphyromonas gingivalis invasion of gingival epithelial cells. Infect Immun. 1995; 63: 3878–85.
   PubMed Web of Science ®Google Scholar
• Amano A. Disruption of epithelial barrier and impairment of cellular function by Porphyromonas gingivalis. Front Biosci. 2007; 1: 3965–74.
   Google Scholar
• Yang HW, Huang YF, Chan Y, Chou MY. Relationship of Actinobacillus actinomycetemcomitans serotypes to periodontal condition: prevalence and proportions in subgingival plaque. Eur J Oral Sci. 2005; 113: 28–33.
   Web of Science ®Google Scholar
• Ji S, Hyun J, Park E, Lee B-L, Kim K-K, Choi Y. Susceptibility of various oral bacteria to antimicrobial peptides and to phagocytosis by neutrophils. J Periodontal Res. 2007; 42: 410–9.
   PubMed Web of Science ®Google Scholar
• Taguchi Y, Imai H. Expression of beta-defensin-2 in human gingival epithelial cells in response to challenge with Porphyromonas gingivalis in vitro. J Periodontal Res. 2006; 41: 334–9.
   Web of Science ®Google Scholar
• Diamond G, Beckloff N, Ryan LK. Host defense peptides in the oral cavity and the lung: similarities and differences. J Dent Res. 2008; 87: 915–27.
   PubMed Web of Science ®Google Scholar
• Krisanaprakornkit S, Weinberg A, Perez CN, Dale BA. Expression of the peptide antibiotic human beta-defensin 1 in cultured gingival epithelial cells and gingival tissue. Infect Immun. 1998; 66: 4222–8.
   PubMed Web of Science ®Google Scholar
• Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, et al.. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1. Nature. 2011; 469: 419–23.
   PubMed Web of Science ®Google Scholar
• Schroeder BO, Stange EF, Wehkamp J. Waking the wimp: Redox modification activates human beta-defensin 1. Gut Microbes. 2011; 2: 262–6.
   PubMedGoogle Scholar
• Angelini G, Gardella S, Ardy M, Ciriolo MR, Filomeni G, Di Trapani G, et al.. Antigen-presenting dendritic cells provide the reducing extracellular microenvironment required for T lymphocyte activation. Proc Natl Acad Sci U S A. 2002; 99: 1491–6.
   PubMed Web of Science ®Google Scholar
• Steeves CH, Potrykus J, Barnett DA, Bearne SL. Oxidative stress response in the opportunistic oral pathogen Fusobacterium nucleatum. Proteomics. 2011; 11: 2027–37.
   Web of Science ®Google Scholar
• Kanda N, Kamata M, Tada Y, Ishikawa T, Sato S, Watanabe S. Human β-defensin-2 enhances IFN-γ and IL-10 production and suppresses IL-17 production in T cells. J Leukoc Biol. 2011; 89: 935–44.
   Web of Science ®Google Scholar
• Soruri A, Grigat J, Forssmann U, Riggert J, Zwirner J. Defensins chemoattract macrophages and mast cells but not lymphocytes and dendritic cells: CCR6 is not involved. Eur J Immunol. 2007; 37: 2474–86.
   PubMed Web of Science ®Google Scholar
• Yin L, Chino T, Horst OV, Hacker BM, Clark EA, Dale BA, et al.. Differential and coordinated expression of defensins and cytokines by gingival epithelial cells and dendritic cells in response to oral bacteria. BMC Immunol. 2010; 11: 37.
   Google Scholar
• Nishimura M, Abiko Y, Kurashige Y, Takeshima M, Yamazaki M, Kusano K, et al.. Effect of defensin peptides on eukaryotic cells: primary epithelial cells, fibroblasts, and squamous cell carcinoma cell lines. J Dermatol Sci. 2004; 36: 87–95.
   Web of Science ®Google Scholar
• Chotjumlong P, Khongkhunthian S, Ongchai S, Reutrakul V, Krisanaprakornkit S. Human β-defensin-3 up-regulates cyclooxygenase-2 expression and prostaglandin E2 synthesis in human gingival fibroblasts. J Periodontal Res. 2010; 45: 464–70.
   Web of Science ®Google Scholar
• Semple F, Webb S, Li HN, Patel HB, Perretti M, Jackson IJ, et al.. Human β-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol. 2010; 40: 1073–8.
   PubMed Web of Science ®Google Scholar
• Häkkinen L, Uitto VJ, Larjava H. Cell biology of gingival wound healing. Periodontol. 2000; 24: 127–52.
   Google Scholar
• Niyonsaba F, Ushio H, Nakano N, Ng W, Sayama K, Hashimoto K, et al.. Antimicrobial peptides human β-defensins stimulate epidermal keratinocyte migration, proliferation, and production of proinflammatory cytokines and chemokines. J Invest Dermatol. 2007; 127: 594–604.
   PubMed Web of Science ®Google Scholar
• Otte JM, Werner I, Brand S, Chromik AM, Schmitz F, Kleine M, et al.. Human beta defensin 2 promotes intestinal wound healing in vitro. J Cell Biochem. 2008; 104: 2286–97.
   PubMed Web of Science ®Google Scholar
• Lu Q, Samaranayake L, Darveau R, Jin L. Expression of β-defensin-3 in gingival epithelia. J Periodontal Res. 2005; 40: 474–81.
   PubMed Web of Science ®Google Scholar
• Supp DM, Karpinski AC, Boyce ST. Expression of human β-defensin HBD-1, HBD-2, and HBD-3 in cultured keratinocytes and skin substitutes. Burns. 2004; 30: 643–8.
   Web of Science ®Google Scholar
• Gursoy UK, Pöllänen M, Könönen E, Uitto VJ. A novel organotypic dento-epithelial culture model: Effect of Fusobacterium nucleatum biofilm on β-defensin-2, -3, and LL-37 expression. J Periodontol. 2012; 83: 242–7.
   PubMed Web of Science ®Google Scholar
• Lu Q, Jin L, Darveau RP, Samaranayake LP. Expression of human β-defensins-1 and -2 peptides in unresolved chronic periodontitis. J Periodontal Res. 2004; 39: 221–7.
   Web of Science ®Google Scholar
• Bissell J, Joly S, Johnson GK, Organ CC, Dawson D, McCray PB Jr, et al.. Expression of β-defensins in gingival health and in periodontal disease. J Oral Pathol Med. 2004; 33; 278–85.
   Web of Science ®Google Scholar
• Hosokawa I, Hosokawa Y, Komatsuzawa H, Goncalves RB, Karimbux N, Napimoga MH, et al.. Innate immune peptide LL-37 displays distinct expression pattern from beta-defensins in inflamed gingival tissue. Clin Exp Immunol. 2006; 146: 218–25.
   PubMed Web of Science ®Google Scholar
• Offenbacher S, Barros SP, Paquette DW, Winston JL, Biesbrock AR, Thomason RG, et al.. Gingival transcriptome patterns during induction and resolution of experimental gingivitis in humans. J Periodontol. 2009; 80: 1963–82.
   PubMed Web of Science ®Google Scholar
• Dunsche A, Açil Y, Dommisch H, Siebert R, Schröder JM, Jepsen S. The novel human beta-defensin-3 is widely expressed in oral tissues. Eur J Oral Sci. 2002; 110: 121–4.
   PubMed Web of Science ®Google Scholar
• Kuula H, Salo T, Pirilä E, Hagström J, Luomanen M, Gutierrez-Fernandez A, et al.. Human β-defensin-1 and -2 and matrix metalloproteinase-25 and -26 expression in chronic and aggressive periodontitis and in peri-implantitis. Arch Oral Biol. 2008; 53: 175–86.
   Web of Science ®Google Scholar
• Brancatisano FL, Maisetta G, Barsotti F, Esin S, Miceli M, Gabriele M, et al.. Reduced human beta defensin 3 in individuals with periodontal disease. J Dent Res. 2011; 90: 241–5.
   Web of Science ®Google Scholar
• Taggart CC, Greene CM, Smith SG, Levine RL, McCray PB Jr, O'Neill S, et al.. Inactivation of human β-defensins 2 and 3 by elastolytic cathepsins. J Immunol. 2003; 171: 931–7.
   PubMed Web of Science ®Google Scholar
• Brissette CA, Simonson LG, Lukehart SA. Resistance to human β-defensins is common among oral treponemes. Oral Microbiol Immunol. 2004; 19: 403–7.
   Google Scholar
• Rivas-Santiago B, Serrano CJ, Enciso-Moreno JA. Susceptibility to infectious diseases based on antimicrobial peptide production. Infect Immun. 2009; 77: 4690–5.
   PubMed Web of Science ®Google Scholar
• Jurevic RJ, Bai M, Chadwick RB, White TC, Dale BA. Single-nucleotide polymorphisms (SNPs) in human β-defensin 1: high-throughput SNP assays and association with Candida carriage in type I diabetics and nondiabetic controls. J Clin Microbiol. 2003; 41: 90–6.
   PubMed Web of Science ®Google Scholar
• Ozturk A, Famili P, Vieira AR. The antimicrobial peptide DEFB1 is associated with caries. J Dent Res. 2010; 89: 631–6.
   PubMed Web of Science ®Google Scholar
• Tiszlavicz Z, Szabolcs A, Takács T, Farkas G, Kovács-Nagy R, Szántai E, et al.. Polymorphisms of beta defensins are associated with the risk of severe acute pancreatitis. Pancreatology. 2010; 10: 483–90.
   Web of Science ®Google Scholar
• Wang H, Watanabe H, Ogita M, Ichinose S, Izumi Y. Effect of human β-defensin-3 on the proliferation of fibroblasts on periodontally involved root surfaces. Peptides. 2011; 32: 888–94.
   PubMed Web of Science ®Google Scholar